Bux Pain Management Treats First Commercial Patient in the Nation Using Spark Biomedical’s Sparrow Therapy System
February 03, 2021 15:34 ET | Spark Biomedical
Danville, KY, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Dr. Anjum Bux, a leading expert in pain management, was the first in the nation to successfully treat commercial patients using Transcutaneous...
2020-0227 Cognition Logo for GNW.png
Cognition Therapeutics Publishes Evidence Identifying Receptor Integral in Parkinson’s Disease Pathology
February 01, 2021 08:00 ET | Cognition Therapeutics, Inc.
PITTSBURGH, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
NOVARTIS logo.jpg
Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis
January 29, 2021 12:05 ET | Novartis International AG
 Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS1CHMP opinion is based on...
logo.png
German University Hospital Orders Nexstim NBS System with NexSpeech
January 28, 2021 04:40 ET | Nexstim Oyj
Press release, Helsinki, 28 January 2021 at 11.40 am (EET) German University Hospital Orders Nexstim NBS System with NexSpeech Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces...
Spark Biomedical’s Sparrow Therapy System™ receives FDA Clearance for Opioid Withdrawal Relief in Adults
January 04, 2021 16:38 ET | Spark Biomedical
Dallas, TX, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc. announced today that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to The Sparrow Therapy System, a...
logo.png
Nexstim Plc signs a purchase agreement worth EUR 0.9 million to develop and deliver two prototype systems for a research project
November 18, 2020 04:00 ET | Nexstim Oyj
Company announcement, Inside information, Helsinki, 18 November 2020 at 11.00 am (EET) Nexstim Plc signs a purchase agreement worth EUR 0.9 million to develop and deliver two prototype systems for a...
logo.png
Nexstim Oyj on allekirjoittanut 0,9 miljoonan euron arvoisen sopimuksen kahden prototyyppilaitteiston kehittämisestä ja toimittamisesta tutkimusprojektia varten
November 18, 2020 04:00 ET | Nexstim Oyj
Yhtiötiedote, sisäpiiritieto, Helsinki, 18.11.2020 klo 11.00 (EET) Nexstim Oyj on allekirjoittanut 0,9 miljoonan euron arvoisen sopimuksen kahden prototyyppilaitteiston kehittämisestä ja...
logo.png
Nexstim Abp tecknar avtal värt 0,9 miljoner euro om framtagning och leverans av två prototypsystem för forskningsprojekt
November 18, 2020 04:00 ET | Nexstim Oyj
Företagsmeddelande, insiderinformation, Helsingfors, 18.11.2020 kl. 11.00 (EET) Nexstim Abp tecknar avtal värt 0,9 miljoner euro om framtagning och leverans av två prototypsystem för...
DENALI LOGO FOR PRESS RELEASE.jpg
Denali Therapeutics Announces First Human Biomarker Proof of Concept for Its Transport Vehicle (TV) Technology Achieved in Phase 1/2 Study of ETV:IDS (DNL310) in Hunter Syndrome (MPS II)
November 10, 2020 07:30 ET | Denali Therapeutics Inc.
After four weekly intravenous doses of DNL310, a 76% mean reduction in CSF GAG levels (heparan sulfate) from baseline was observed, with normal healthy levels being achieved in four of five...
NOVARTIS logo.jpg
Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention
November 02, 2020 01:15 ET | Novartis International AG
The first randomized, double blind, head-to-head study of Aimovig® (erenumab) against topiramate in patients with episodic and chronic migraine (HER-MES) achieved superiority in its primary and...